Abstract
Purpose: This study aimed to evaluate the efficacy of photodynamic therapy (PDT) in treating chronic central serous chorioretinopathy (CSC). Methods: We describe a non-randomized, multicentre, interventional case series. A total of 82 eyes of 72 patients with chronic CSC were treated by conventional PDT. LogMAR best corrected visual acuity (BCVA) (ETDRS charts) and central foveal thickness (CFT) measured by optical coherence tomography before and after PDT, number of PDT treatments and complications were used as outcome indicators. Results: Mean follow-up was 12 ± 10 months and mean age was 46 ± 10 years. Mean logMAR BCVA changed from 0.53 (standard deviation [SD] 0.43) before PDT to 0.38 (SD 0.41) at 3 months and 0.48 (SD 0.50) at 6 months (p <0.0001 and p = 0.007, respectively, Student's t-test for paired data). Mean BCVA at the end of follow-up was 0.37 (SD 0.45; p <0.0001 from baseline). Macular detachment was resolved and subretinal fluid (SRF) disappeared in all cases. Central foveal thickness decreased from 325 μm (SD 95), to 229 μm (SD 70) at 1 month after PDT, 206 μm (SD 68) at 3 months, and 202 μm (SD 76) at 6 months (all p <0.0001, Student's t-test for paired data). No cases developed severe visual loss or complications derived from PDT. Reactive retinal pigment epithelium hypertrophy appeared in nine cases after PDT. Conclusions: Photodynamic therapy with verteporfin may be useful in chronic CSC for improving BCVA and reducing SRF and CFT. Randomized studies with longer follow-up are needed to assess the real role of this treatment in chronic CSC.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 371-376 |
| Number of pages | 6 |
| Journal | Acta Ophthalmologica |
| Volume | 88 |
| Issue number | 3 |
| DOIs | |
| State | Published - May 2010 |
| Externally published | Yes |
Fingerprint
Keywords
- Central serous chorioretinopathy
- Optical coherence tomography
- Photodynamic therapy
- Retinal pigment epithelium
ASJC Scopus subject areas
- Ophthalmology
Cite this
Photodynamic therapy for chronic central serous chorioretinopathy. / Ruiz-Moreno, José M.; Lugo, Francisco L.; Armadá, Felix; Silva, Rufino; Montero, Javier A.; Arevalo, J Fernando; Arias, Luis; Gómez-Ulla, Francisco.
In: Acta Ophthalmologica, Vol. 88, No. 3, 05.2010, p. 371-376.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Photodynamic therapy for chronic central serous chorioretinopathy
AU - Ruiz-Moreno, José M.
AU - Lugo, Francisco L.
AU - Armadá, Felix
AU - Silva, Rufino
AU - Montero, Javier A.
AU - Arevalo, J Fernando
AU - Arias, Luis
AU - Gómez-Ulla, Francisco
PY - 2010/5
Y1 - 2010/5
N2 - Purpose: This study aimed to evaluate the efficacy of photodynamic therapy (PDT) in treating chronic central serous chorioretinopathy (CSC). Methods: We describe a non-randomized, multicentre, interventional case series. A total of 82 eyes of 72 patients with chronic CSC were treated by conventional PDT. LogMAR best corrected visual acuity (BCVA) (ETDRS charts) and central foveal thickness (CFT) measured by optical coherence tomography before and after PDT, number of PDT treatments and complications were used as outcome indicators. Results: Mean follow-up was 12 ± 10 months and mean age was 46 ± 10 years. Mean logMAR BCVA changed from 0.53 (standard deviation [SD] 0.43) before PDT to 0.38 (SD 0.41) at 3 months and 0.48 (SD 0.50) at 6 months (p <0.0001 and p = 0.007, respectively, Student's t-test for paired data). Mean BCVA at the end of follow-up was 0.37 (SD 0.45; p <0.0001 from baseline). Macular detachment was resolved and subretinal fluid (SRF) disappeared in all cases. Central foveal thickness decreased from 325 μm (SD 95), to 229 μm (SD 70) at 1 month after PDT, 206 μm (SD 68) at 3 months, and 202 μm (SD 76) at 6 months (all p <0.0001, Student's t-test for paired data). No cases developed severe visual loss or complications derived from PDT. Reactive retinal pigment epithelium hypertrophy appeared in nine cases after PDT. Conclusions: Photodynamic therapy with verteporfin may be useful in chronic CSC for improving BCVA and reducing SRF and CFT. Randomized studies with longer follow-up are needed to assess the real role of this treatment in chronic CSC.
AB - Purpose: This study aimed to evaluate the efficacy of photodynamic therapy (PDT) in treating chronic central serous chorioretinopathy (CSC). Methods: We describe a non-randomized, multicentre, interventional case series. A total of 82 eyes of 72 patients with chronic CSC were treated by conventional PDT. LogMAR best corrected visual acuity (BCVA) (ETDRS charts) and central foveal thickness (CFT) measured by optical coherence tomography before and after PDT, number of PDT treatments and complications were used as outcome indicators. Results: Mean follow-up was 12 ± 10 months and mean age was 46 ± 10 years. Mean logMAR BCVA changed from 0.53 (standard deviation [SD] 0.43) before PDT to 0.38 (SD 0.41) at 3 months and 0.48 (SD 0.50) at 6 months (p <0.0001 and p = 0.007, respectively, Student's t-test for paired data). Mean BCVA at the end of follow-up was 0.37 (SD 0.45; p <0.0001 from baseline). Macular detachment was resolved and subretinal fluid (SRF) disappeared in all cases. Central foveal thickness decreased from 325 μm (SD 95), to 229 μm (SD 70) at 1 month after PDT, 206 μm (SD 68) at 3 months, and 202 μm (SD 76) at 6 months (all p <0.0001, Student's t-test for paired data). No cases developed severe visual loss or complications derived from PDT. Reactive retinal pigment epithelium hypertrophy appeared in nine cases after PDT. Conclusions: Photodynamic therapy with verteporfin may be useful in chronic CSC for improving BCVA and reducing SRF and CFT. Randomized studies with longer follow-up are needed to assess the real role of this treatment in chronic CSC.
KW - Central serous chorioretinopathy
KW - Optical coherence tomography
KW - Photodynamic therapy
KW - Retinal pigment epithelium
UR - http://www.scopus.com/inward/record.url?scp=77951722846&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77951722846&partnerID=8YFLogxK
U2 - 10.1111/j.1755-3768.2008.01408.x
DO - 10.1111/j.1755-3768.2008.01408.x
M3 - Article
C2 - 19958296
AN - SCOPUS:77951722846
VL - 88
SP - 371
EP - 376
JO - Acta Ophthalmologica
JF - Acta Ophthalmologica
SN - 0001-639X
IS - 3
ER -